BLISSGVS.NS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 12:00):

Stats
Dagens volum	640 400
Gjennomsnittsvolum	633 253
Markedsverdi	13.04B
EPS	INR0 ( 2024-01-22 )
Neste inntjeningsdato	( INR0 ) 2024-05-08
Last Dividend	INR0.500 ( 2023-07-12 )
Next Dividend	INR0 ( N/A )
P/E	15.01
ATR14	INR0.177 (0.14%)

Volum Korrelasjon

Lang: 0.06 (neutral)

Kort: -0.91 (very strong negative)

Signal:(43.67) Neutral

Bliss GVS Pharma Limited Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Bliss GVS Pharma Limited Korrelasjon - Valuta/Råvare

-0.02
( neutral )

-0.03
( neutral )

0.00
( neutral )

0.12
( neutral )

-0.79
( moderate negative )

0.02
( neutral )

Bliss GVS Pharma Limited Økonomi

Annual	2022
Omsetning:	INR7.52B
Bruttogevinst:	INR3.50B (46.60 %)
EPS:	INR6.83

FY	2022
Omsetning:	INR7.52B
Bruttogevinst:	INR3.50B (46.60 %)
EPS:	INR6.83

FY	2022
Omsetning:	INR7.38B
Bruttogevinst:	INR3.47B (47.02 %)
EPS:	INR2.24

FY	2021
Omsetning:	INR5.69B
Bruttogevinst:	INR2.40B (42.16 %)
EPS:	INR6.64

Financial Reports:

No articles found.

Bliss GVS Pharma Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0.500 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Bliss GVS Pharma Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.34 - low (44.24%) | Divividend Growth Potential Score: 4.24 - Stable (15.12%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.300	2010-11-25
Last Dividend	INR0.500	2023-07-12
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	19	--
Total Paid Out	INR9.35	--
Avg. Dividend % Per Year	0.46%	--
Score	2.16	--
Div. Sustainability Score	4.34
Div.Growth Potential Score	4.24
Div. Directional Score	4.29	--

Next Divdend (Est)
(2024-12-10)

INR0.496 Estimate 3.25 %

Dividend Stability

0.26 Very Poor

Dividend Score

2.16

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR1.000	0.48%
2019	INR1.000	0.61%
2020	INR0.500	0.34%
2021	INR1.000	0.49%
2022	INR1.000	0.96%
2023	INR0.500	0.69%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
APOLSINHOT.NS	Dividend Junior	2023-09-22	Annually	10	0.11%
TDPOWERSYS.NS	Dividend Junior	2023-08-02	Annually	13	0.31%
OLECTRA.NS	Dividend Junior	2023-09-21	Sporadic	23	0.03%
INTENTECH.NS	Dividend Junior	2023-09-21	Annually	6	0.44%
COROMANDEL.NS	Dividend Knight	2023-07-13	Annually	19	1.02%
SHALBY.NS	Dividend Junior	2023-08-08	Annually	6	0.51%
MANALIPETC.NS	Dividend Junior	2023-09-15	Annually	18	1.50%
GPPL.NS	Dividend Knight	2023-07-26	Semi-Annually	9	2.89%
AXISBANK.NS	Dividend Junior	2023-07-06	Sporadic	26	0.06%
TRU.NS	Dividend Junior	2023-09-18	Annually	3	0.01%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.116	1.500	7.68	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.129	1.500	9.68	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	12.33	1.000	6.54	6.54	[3 - 30]
operatingCashFlowPerShareTTM	2.70	2.00	9.10	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.70	2.00	8.65	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.477	1.000	5.38	5.38	[0.2 - 0.8]
operatingProfitMarginTTM	0.165	1.000	8.69	8.69	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.34

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	14.84	1.000	8.60	0	[1 - 100]
returnOnEquityTTM	0.129	2.50	9.79	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.70	2.00	9.10	10.00	[0 - 30]
dividendYielPercentageTTM	0.401	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.70	2.00	9.10	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0403	1.500	-3.06	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0373	1.000	-1.566	0	[0.1 - 0.5]
Total Score				4.24

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, creams, lotions, lozenges, nasal inhalers, over the counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, solutions, sprays, syrups, and vaginal washes. In addition, it offers therapeutic products consisting of anti-bacterial, anti-dandruff shampoo, amino acid preparation, iron tonic, antitussive, appetite stimulant, anti-allergic, body supplement, anti-biotic, anti-diabetic, anti-diarrheal, anti-emetic, anti-fungal, anti-haemorrhoidal, anti-helmintic, anti-infective, anti-inflammatory, anti-malarial, anti-microbial, anti-migraine, anti-oxidant, anti-protozoal, ear wax solvent, anti-pyretic, anti-septic, anti-spasmodic, anti-ulcer, and anti-ulcerant; and analgesic, oral rehydration, antacid, anxiolytic, appetizer, cough syrup, erectile dysfunction, haematinic, hand sanitizer, health supplement, insecticide, laryngitis, pharyngitis, laxative, lubricant, mosquito repellant, nasal decongestant, nutritional supplement, moisturizer, prickly heat powder, skin lightening lotion, vaginal contraceptive, vaginal hygiene, and vitamin supplements, as well as medicated, complexion, moisturizing, and total protection soaps. The company also exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.